Lung Cancer

LUNGevity answers some frequently asked questions about patients with lung cancer and survivors and the coronavirus illness.

In this series of videos from LUNGevity, oncologist Zosia Piotrowska, MD, MHS, Massachusetts General Hospital, Boston, addresses many of the questions and concerns raised in regard to coronavirus COVID-19 and patients with lung cancer.

Oncologist Dr. Zosia Piotrowska addresses some specific questions about the impact of COVID-19. She discusses dealing with anxiety, symptoms, who is most at risk for the illness, how it is spread, how to avoid getting the illness, and the available treatments.

Dr. Zosia Piotrowska explains why COVID-19 is of special concern for patients with lung cancer and their caregivers. She addresses the question of treatment-related compromised immunity and the illness.

Some of the most frequently asked questions about COVID-19 include travel, social distancing, and other day-to-day matters for patients with lung cancer. Oncologist Dr. Zosia Piotrowska provides some answers.

Dr. Joan Schiller, like many cancer care advocates, is working to change the negative attitudes and misconceptions about lung cancer, which is often seen as being caused by the patient, but in reality affects many people who never have smoked.

Here are the drugs and financial support services available to patients receiving treatment for Lung Cancer.

After getting tested for genetic abnormalities, Brandi Bryant learned she had the ALK genetic mutation, which increases the risk for lung cancer. This information resulted in important changes in her treatment and led her to become an advocate for genetic testing, especially among minority communities.

Late in 2019, the FDA approved the combination of immunotherapy plus chemotherapy as the first-line treatment for patients with non–small-cell lung cancer that does not harbor EGFR or ALK mutations, which are often associated with lung cancer.